Inherited metabolic disorders
Infantile Krabbe disease
Also called: IKD · EIKD · infantile GLD · GALC deficiency · Krabbe disease · globoid cell leukodystrophy · Early-infantile globoid cell leukodystrophy · Infantile galactocerebrosidase deficiency
What a donor has to do with this
For some people with this condition, a transplant using blood stem cells from an unrelated donor is part of the treatment guidelines. When a transplant is the right route and no one in the family matches, that donor comes from a registry. Not everyone with this condition has a transplant, and many never need one.
This is our reading of published transplant guidelines for this condition, not a measurement of how many people need a donor. Where a source actually counted donors, the figure and the people it counted are shown further down. Where none did, we say so rather than estimate.
This page is not written out in full yet
We have not written this condition out in full yet. What is on this page — how a donor fits in, who it affects, and the sources behind that — is researched and linked, but the plain-English explanation of the condition itself is still to come.
What the evidence says
- Who it affects
- Typical onset/diagnosis: the infantile form is the most common and usually begins before age 1. Evidence: U.S. NIH GARD synthesis (updated 2026); no markedly enriched population was identified.
- Treatments other than a transplant
- Supportive neurologic, nutritional, respiratory, and palliative care — noncurative management — multiple regions — No approved gene therapy at the evidence cutoff.
- If a transplant is used, the cells come from
- bone marrow: used; mobilized peripheral blood stem cells: rarely used in lysosomal-storage-disease HCT guidance; umbilical cord blood: used and often preferred in lysosomal-storage-disease HCT guidance; dominance: umbilical cord blood is the preferred source in the opened EBMT lysosomal-storage-disease guidance
- How often the donor was unrelated
- Not reported. No source we could read states this for this condition, so we do not give a number. An estimate here would be a guess dressed as evidence.
Where this gets complicated
Newborn-screening biochemical risk strata have imperfect positive predictive value, creating a difficult risk-benefit threshold for immediate HCT.; Survival improves with presymptomatic treatment, but motor disability can still progress and normal neurodevelopment is not guaranteed.
“The cells for an allogeneic transplant can come from a family member, unrelated donor or umbilical cord blood.”
It describes what teams consider in general. It cannot say what applies to any one person. Read the source.
Registries need people
Joining a registry is a cheek swab and a short health form. You are not matched to a condition — you are matched to a person, and it could be someone with any of the conditions in this library. You are contacted only if you turn out to be a possible match for someone, and you can ask questions and decline before anything else happens.
Related conditions
Others in inherited metabolic disorders. They are genuinely different diseases with different treatments — the group name is not a diagnosis.
Where this came from
- Galactosylceramide beta-galactosidase deficiency (Krabbe disease) — NIH NCATS GARD, updated 2026-06
- EBMT Handbook, Chapter 91: Inborn Errors of Metabolism and Osteopetrosis — EBMT/Springer, 2024-04-11
- Krabbe disease and transplant — NMDP, accessed 2026-07-31